SG11201503526UA - Dual glp1/gip or trigonal glp1/gip/glucagon agonists - Google Patents

Dual glp1/gip or trigonal glp1/gip/glucagon agonists

Info

Publication number
SG11201503526UA
SG11201503526UA SG11201503526UA SG11201503526UA SG11201503526UA SG 11201503526U A SG11201503526U A SG 11201503526UA SG 11201503526U A SG11201503526U A SG 11201503526UA SG 11201503526U A SG11201503526U A SG 11201503526UA SG 11201503526U A SG11201503526U A SG 11201503526UA
Authority
SG
Singapore
Prior art keywords
gip
glp1
trigonal
dual
glucagon agonists
Prior art date
Application number
SG11201503526UA
Inventor
Torsten Haack
Michael Wagner
Bernd Henkel
Siegfried Stengelin
Andreas Evers
Martin Lorenz
Katrin Lorenz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201503526UA publication Critical patent/SG11201503526UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201503526UA 2012-12-21 2013-12-19 Dual glp1/gip or trigonal glp1/gip/glucagon agonists SG11201503526UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306647 2012-12-21
PCT/EP2013/077313 WO2014096150A1 (en) 2012-12-21 2013-12-19 Dual glp1/gip or trigonal glp1/gip/glucagon agonists

Publications (1)

Publication Number Publication Date
SG11201503526UA true SG11201503526UA (en) 2015-06-29

Family

ID=47559233

Family Applications (5)

Application Number Title Priority Date Filing Date
SG11201504215PA SG11201504215PA (en) 2012-12-21 2013-12-19 Functionalized exendin-4 derivatives
SG11201503526UA SG11201503526UA (en) 2012-12-21 2013-12-19 Dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG11201503576XA SG11201503576XA (en) 2012-12-21 2013-12-19 Exendin-4 Derivatives
SG11201503524PA SG11201503524PA (en) 2012-12-21 2013-12-19 Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG10201705097PA SG10201705097PA (en) 2012-12-21 2013-12-19 Functionalized exendin-4 derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201504215PA SG11201504215PA (en) 2012-12-21 2013-12-19 Functionalized exendin-4 derivatives

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG11201503576XA SG11201503576XA (en) 2012-12-21 2013-12-19 Exendin-4 Derivatives
SG11201503524PA SG11201503524PA (en) 2012-12-21 2013-12-19 Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
SG10201705097PA SG10201705097PA (en) 2012-12-21 2013-12-19 Functionalized exendin-4 derivatives

Country Status (38)

Country Link
US (5) US9745360B2 (en)
EP (5) EP2934566B1 (en)
JP (4) JP6408998B2 (en)
KR (4) KR20150096398A (en)
CN (4) CN104870009B (en)
AR (5) AR094178A1 (en)
AU (4) AU2013366690B2 (en)
BR (3) BR112015014510A2 (en)
CA (4) CA2895156A1 (en)
CL (2) CL2015001751A1 (en)
CR (1) CR20150358A (en)
CY (2) CY1120030T1 (en)
DK (2) DK2934567T3 (en)
DO (1) DOP2015000156A (en)
EA (1) EA031428B1 (en)
EC (1) ECSP15031141A (en)
ES (2) ES2653765T3 (en)
HK (4) HK1211232A1 (en)
HR (2) HRP20180092T1 (en)
HU (2) HUE035803T2 (en)
IL (4) IL238623A0 (en)
LT (2) LT2934567T (en)
MA (1) MA38276B1 (en)
MX (4) MX362190B (en)
PE (1) PE20151239A1 (en)
PH (1) PH12015501291A1 (en)
PL (2) PL2934568T3 (en)
PT (2) PT2934567T (en)
RS (1) RS57531B1 (en)
RU (3) RU2015129696A (en)
SG (5) SG11201504215PA (en)
SI (2) SI2934568T1 (en)
TN (1) TN2015000283A1 (en)
TW (4) TW201441251A (en)
UA (1) UA116553C2 (en)
UY (4) UY35231A (en)
WO (4) WO2014096149A1 (en)
ZA (1) ZA201503914B (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
WO2014096149A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 Derivatives
ES2865402T3 (en) 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleosides, 4'-fluoronucleotides and analogues thereof for the treatment of HCV
UA111305C2 (en) 2012-12-21 2016-04-11 Пфайзер Інк. Condensed with lactams of aryl and heteroaryl
KR102229051B1 (en) 2013-05-28 2021-03-16 다케다 야쿠힌 고교 가부시키가이샤 Peptide compound
MX2016005556A (en) 2013-11-06 2016-07-15 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods.
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
ME03419B (en) 2014-06-17 2020-01-20 Pfizer Substituted dihydroisoquinolinone compounds
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
JOP20200119A1 (en) 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
KR101661332B1 (en) * 2015-05-28 2016-09-29 (의료)길의료재단 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 receptor agonist
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
SI3389697T1 (en) 2015-12-14 2021-02-26 Antaros Medical Ab Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
JP7026044B2 (en) 2015-12-23 2022-02-25 ザ・ジョンズ・ホプキンス・ユニバーシティー Long-acting GLP-1r agonist for the treatment of neurological and neurodegenerative conditions
CN113546159B (en) 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 Compositions comprising GLP-1 receptor agonists and glucagon receptor agonists and uses thereof
JP6712322B2 (en) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド Triple-acting persistent conjugate having activity on all glucagon, GLP-1 and GIP receptors
KR102460198B1 (en) * 2016-03-10 2022-10-31 메디뮨 리미티드 Glucagon and GLP-1 co-agonists for the treatment of obesity
CA3024962A1 (en) * 2016-05-24 2017-11-30 Takeda Pharmaceutical Company Limited Peptide compound
AU2017289014B2 (en) 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
TW201821434A (en) 2016-10-10 2018-06-16 法商賽諾菲公司 Method of preparing peptides comprising a lipophilically modified lysine side chain
EP3526242A1 (en) * 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
AR110299A1 (en) 2016-12-02 2019-03-13 Sanofi Sa CONJUGATES UNDERSTANDING A DUAL GLP-1 / GLUCAGON AGONIST, A CONNECTOR AND Hyaluronic Acid
AR110300A1 (en) 2016-12-02 2019-03-13 Sanofi Sa COMPOUNDS AS TRIGONAL PEPTIDE AGONISTS OF GLP1 / GLUCAGÓN / GIP RECEPTORS
AR110301A1 (en) 2016-12-02 2019-03-13 Sanofi Sa COMPOUNDS AS GLP1 / GLUCAGÓN / GIP RECEPTING AGENISTS
WO2018153849A1 (en) 2017-02-21 2018-08-30 Sanofi Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Peptide compound
RU2020109881A (en) * 2017-08-09 2021-09-10 Санофи GLP-1 / GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
CN109836488B (en) * 2017-11-24 2022-08-23 浙江道尔生物科技有限公司 Glucagon analogues for treating metabolic diseases
GB201720187D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
CA3095988A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
JP7332620B2 (en) 2018-04-10 2023-08-23 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Synthesis of lixisenatide with capping
JP7434169B2 (en) 2018-04-10 2024-02-20 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Method for cleaving solid phase-bound peptides from solid phase
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
UY38249A (en) 2018-05-30 2019-12-31 Sanofi Sa CONJUGATED PRODUCTS INCLUDING A TRIPLE GLP-1 / GLUCAGON / GIP RECEPTOR AGONIST, A CONNECTOR AND HYALURONIC ACID
KR102119188B1 (en) * 2018-11-13 2020-06-08 이뮤노포지 주식회사 Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1, GLP-1 derived peptide, or GLP-1 degradation inhibitor
MX2021007444A (en) 2018-12-21 2021-08-05 Jiangsu Hengrui Medicine Co Bispecific protein.
JP2022515229A (en) * 2018-12-21 2022-02-17 ハンミ ファーマシューティカル カンパニー リミテッド A pharmaceutical composition comprising insulin and a triple active agent having activity on all of glucagon, GLP-1 and GIP receptors.
JP7324530B2 (en) * 2019-01-07 2023-08-10 鴻緒生物医葯科技（北京）有限公司 Novel polypeptides and their therapeutic uses
EP3954701A4 (en) * 2019-04-11 2023-09-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
WO2020214013A1 (en) * 2019-04-19 2020-10-22 한미약품 주식회사 Therapeutic use, for hyperlipideamia, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
WO2020214012A1 (en) * 2019-04-19 2020-10-22 한미약품 주식회사 Preventive or therapeutic pharmaceutical composition for hyperlipidemia comprising triple agonist acting on all of glucagon, glp-1 and gip receptors, or conjugate thereof, and preventive or therapeutic method
GB201908424D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
KR20220066056A (en) 2019-08-16 2022-05-23 어플라이드 몰레큘라 트랜스포트 인크. Compositions, Formulations, and Interleukin Preparation and Tablets
CN111040022B (en) * 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 Triplex agonists directed to glucagon-like peptide-1 receptor, glucagon receptor, and pepstatin receptor
AU2021211451B2 (en) * 2020-01-23 2023-11-02 Eli Lilly And Company GIP/GLP1 co-agonist compounds
JP2023519516A (en) 2020-03-06 2023-05-11 サノフイ Peptides as selective GIP receptor agonists
JP2023520769A (en) 2020-03-31 2023-05-19 アンタロス メディカル アクティエボラーグ Selective GIP receptor agonists containing chelating moieties for imaging and therapeutic purposes
JP2023521491A (en) * 2020-04-20 2023-05-24 ハンミ ファーマシューティカル カンパニー リミテッド A pharmaceutical composition for prevention or treatment of hyperlipidemia and a method for prevention or treatment containing a triple activator or a conjugate thereof having activity against all of glucagon, GLP-1 and GIP receptor
WO2021239082A1 (en) * 2020-05-29 2021-12-02 北京拓界生物医药科技有限公司 Dual-agonist compound for both glp-1 and gip receptors and application thereof
US20230263896A1 (en) * 2020-07-06 2023-08-24 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic use thereof
CN116133677A (en) * 2020-07-06 2023-05-16 鸿绪生物医药科技（北京）有限公司 Novel polypeptide formulations and therapeutic uses thereof
US20220177538A1 (en) 2020-07-22 2022-06-09 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
JP2023534130A (en) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス GLP-1 receptor and GIP receptor co-agonist
CN116390938A (en) * 2020-08-12 2023-07-04 Txp制药股份有限公司 Exendin-4 analogues
US20230391845A1 (en) 2020-10-30 2023-12-07 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
CN114617956B (en) * 2020-12-10 2023-10-03 江苏中新医药有限公司 High-efficiency hypoglycemic protein medicine
AU2022245736A1 (en) * 2021-03-25 2023-10-12 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
CN117062618A (en) * 2021-05-26 2023-11-14 联邦生物科技(珠海横琴)有限公司 Multiple agonists and uses thereof
CN115572326A (en) * 2021-06-21 2023-01-06 广东东阳光药业有限公司 Triplex agonists of GLP-1, GCG and GIP receptors
TW202313667A (en) * 2021-07-30 2023-04-01 大陸商南京明德新藥研發有限公司 Polypeptide compound containing lactamide bridge
WO2023031455A1 (en) 2021-09-06 2023-03-09 Sanofi Sa New peptides as potent and selective gip receptor agonists
WO2023098777A1 (en) * 2021-12-01 2023-06-08 江苏恒瑞医药股份有限公司 Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
TW202330584A (en) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 Prodrugs and uses thereof
CN117603364A (en) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 GLP-1/glucon/Y 2 Receptor triple agonists and uses thereof

Family Cites Families (437)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
AU4063697A (en) 1996-08-08 1998-02-25 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
ATE356830T1 (en) 1996-08-30 2007-04-15 Novo Nordisk As GLP-1 DERIVATIVES
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2277112C (en) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1019077B2 (en) 1997-08-08 2010-12-22 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
ES2294822T3 (en) 1997-11-14 2008-04-01 Amylin Pharmaceuticals, Inc. NEW COMPOUNDS OF EXENDINE AGONISTS.
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
WO1999025728A1 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DK1044015T3 (en) 1998-01-09 2008-12-08 Amylin Pharmaceuticals Inc Formulations with amylin agonist peptides and insulin
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1950223A3 (en) 1998-03-09 2009-05-13 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
SK19042000A3 (en) 1998-06-12 2001-11-06 Bionebraska, Inc. Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance
ES2335066T3 (en) 1998-08-10 2010-03-18 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services DIFFERENTIATION OF NON-INSULIN CELL PRODUCTS IN GLP-1 OR EXENDIN-4 INSULIN CELLS AND USING THEMSELVES.
CA2343268A1 (en) 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EP1140148B1 (en) 1998-12-22 2005-10-26 Eli Lilly And Company Shelf-stable solution formulation of glucagon-like peptide-1
EP1143989B1 (en) 1999-01-14 2006-12-13 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
PT1140145E (en) 1999-01-14 2005-11-30 Amylin Pharmaceuticals Inc NEW FORMULATIONS OF EXENDINA AGONISTS AND METHODS FOR ITS ADMINISTRATION
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
NZ514916A (en) 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP4115671B2 (en) 1999-05-17 2008-07-09 コンジュケム バイオテクノロジーズ インコーポレイテッド Long-lasting insulinotropic peptides
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
CA2396157A1 (en) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
WO2001068112A2 (en) 2000-03-14 2001-09-20 Goeke Burkhard Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
WO2001087322A2 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
DE60134403D1 (en) 2000-05-19 2008-07-24 Amylin Pharmaceuticals Inc TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
AU2001284985A1 (en) 2000-08-18 2002-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7507714B2 (en) 2000-09-27 2009-03-24 Bayer Corporation Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
DE60142351D1 (en) 2000-10-20 2010-07-22 Amylin Pharmaceuticals Inc TREATMENT OF HYPOACTIVE MYOKARD AND DIABETIC HEART MYOPATHY WITH A GLP-1 PEPTIDE
DE60139430D1 (en) 2000-12-07 2009-09-10 Lilly Co Eli GLP-1 fusion proteins
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
CN1162446C (en) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 Insulinotropic hormone secretion peptide derivative
WO2002098348A2 (en) 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
DK1412384T3 (en) 2001-06-28 2008-04-28 Novo Nordisk As Stable formulation of modified GLP-1
ATE421091T1 (en) 2001-07-16 2009-01-15 Caprotec Bioanalytics Gmbh CAUGHT COMPOUNDS, THEIR COLLECTION AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
CN1571676A (en) 2001-10-19 2005-01-26 伊莱利利公司 Biphasic mixtures of GLP-1 and insulin
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003208945B2 (en) 2002-02-20 2008-05-01 Emisphere Technologies, Inc Method for administering GLP-1 molecules
DK1946776T3 (en) 2002-02-27 2017-03-13 Immunex Corp STABILIZED TNFR-FC COMPOSITION COMPREHENSIVE ARGININE
WO2003077851A2 (en) 2002-03-11 2003-09-25 Hk Pharmaceuticals, Inc. Compounds and methods for analyzing the proteome
US7141240B2 (en) 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
CN1735423A (en) 2002-04-10 2006-02-15 伊莱利利公司 Treatment of gastroparesis
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
WO2003105897A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
US20040037826A1 (en) 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
US20070065469A1 (en) 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
MXPA05000414A (en) 2002-07-09 2005-07-22 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol.
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
EP1545457A4 (en) 2002-08-01 2009-07-01 Mannkind Corp Cell transport compositions and uses thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ME00396B (en) 2002-08-21 2011-05-10 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
KR20050083713A (en) 2002-10-02 2005-08-26 질랜드 파마 에이/에스 Stabilized exendin-4 compounds
US20050209142A1 (en) 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
DK1583541T3 (en) 2002-11-20 2011-04-11 Neuronova Ab Compounds and Methods to Increase Neurogenesis
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
AU2003297356A1 (en) 2002-12-17 2004-07-14 Amylin Pharmaceuticals, Inc. Prevention and treatment of cardiac arrhythmias
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
ES2512499T3 (en) 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Pegylated Reversible Drugs
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
JP4699374B2 (en) 2003-05-15 2011-06-08 トラスティーズ オブ タフツ カレッジ Stable peptide and polypeptide analog therapeutic agents
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PT2644206T (en) 2003-05-23 2019-07-10 Nektar Therapeutics Peg derivatives containing two peg chains
ES2425221T3 (en) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc New methods and compositions for enhanced transmucosal delivery of peptides and proteins
ES2375056T3 (en) 2003-06-03 2012-02-24 Novo Nordisk A/S PEPT� COMPOSITIONS STABILIZED PHARMACEUTICAL DICAS
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101293507B1 (en) 2003-06-03 2013-08-06 노보 노르디스크 에이/에스 Stabilized pharmaceutical peptide compositions
EP2292254A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
MXPA06001283A (en) 2003-08-05 2006-04-11 Novo Nordisk As Novel insulin derivatives.
WO2005019261A1 (en) 2003-08-21 2005-03-03 Novo Nordisk A/S Separation of polypeptides comprising a racemized amino acid
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP4800959B2 (en) 2003-11-13 2011-10-26 ノヴォ ノルディスク アー／エス Soluble pharmaceutical composition for parenteral administration comprising GLP-1 peptide and short-acting insulin peptide for the treatment of diabetes and bulimia
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
SI1687019T1 (en) 2003-11-20 2018-04-30 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2005081619A2 (en) 2003-11-20 2005-09-09 Neuronova Ab Compounds and methods for increasing neurogenesis
CN1902226A (en) 2003-12-03 2007-01-24 诺和诺德公司 Single-chain insulin
JP2007513965A (en) 2003-12-10 2007-05-31 ネクター セラピューティクス アラバマ，コーポレイション Composition comprising two populations of polymer-active agent complex
US20060210614A1 (en) 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
WO2007065156A2 (en) 2005-12-02 2007-06-07 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
CN1938334A (en) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Combined use of a GLP-1 agonist and gastrin compounds
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc Pancreatic polypeptide family motifs and polypeptides comprising the same
EP2233497A3 (en) 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20060110423A1 (en) 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
KR101040415B1 (en) 2004-04-15 2011-06-09 알케르메스,인코포레이티드 Polymer-based sustained release device
WO2005117584A2 (en) 2004-05-28 2005-12-15 Amylin Pharmaceuticals, Inc Improved transmucosal delivery of peptides and proteins
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
CN1950078A (en) 2004-06-11 2007-04-18 诺和诺德公司 Counteracting drug-induced obesity using glp-1 agonists
US20070021346A1 (en) 2005-05-26 2007-01-25 Ewing William R N-terminally modified GLP-1 receptor modulators
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CA2575756A1 (en) 2004-08-03 2006-02-16 Biorexis Technology, Inc. Combination therapy using transferrin fusion proteins comprising glp-1
EP1794512A1 (en) 2004-08-16 2007-06-13 Water Un Limited Apparatus and method for cooling of air
WO2006024631A2 (en) 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
DE102004043153B4 (en) 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin
JP5060131B2 (en) 2004-09-07 2012-10-31 中外製薬株式会社 Method for producing water-soluble hyaluronic acid modified product
JP2008513384A (en) 2004-09-17 2008-05-01 ノボ ノルディスク アクティーゼルスカブ Pharmaceutical composition containing insulin and insulinotropic peptide
MX344532B (en) 2004-10-01 2016-12-19 Ramscor Inc Conveniently implantable sustained release drug compositions.
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
US7595294B2 (en) 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20090036355A1 (en) 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
CN112618700A (en) 2004-11-12 2021-04-09 诺和诺德公司 Stable formulations of insulinotropic peptides
ES2458991T3 (en) 2004-11-12 2014-05-07 Novo Nordisk A/S Stable insulinotropic peptide formulations
EP1841796A2 (en) 2004-12-02 2007-10-10 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2836267C (en) 2004-12-13 2016-06-21 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CN101111267B (en) 2004-12-21 2012-12-05 尼克塔治疗公司 Stabilized polymeric thiol reagents
KR100879662B1 (en) 2004-12-22 2009-01-20 일라이 릴리 앤드 캄파니 Glp-1 analog fusion protein formulations
WO2006073890A2 (en) 2004-12-24 2006-07-13 Amylin Pharmaceuticals, Inc. Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
CN100540565C (en) 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 The Exendins and the application thereof of modifying
US8716221B2 (en) 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
EP1848541A4 (en) 2005-02-07 2013-01-16 Pharmalight Inc Method and device for ophthalmic administration of active pharmaceutical ingredients
JP2008530130A (en) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド GIP analogs and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
DK1888103T3 (en) 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc USE OF GLP-1, EXENDIN AND AGONISTS THEREOF TO DELAY OR PREVENT CARDIAL REMODELING
WO2006114396A1 (en) 2005-04-24 2006-11-02 Novo Nordisk A/S Injection device
EP1888118B1 (en) 2005-05-25 2016-08-17 Novo Nordisk A/S Polypeptide formulations stabilized with ethylenediamine
DK1888031T3 (en) 2005-06-06 2013-02-18 Camurus Ab GLP-1 analog formulations
PL1891105T3 (en) 2005-06-13 2012-09-28 Imperial Innovations Ltd Oxyntomodulin analogues and their effects on feeding behaviour
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1896082B1 (en) 2005-06-16 2012-12-26 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2007019331A2 (en) 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
CN101277722A (en) 2005-08-06 2008-10-01 王庆华 Composition and method for prevention and treatment of type I diabetes
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
FI3524261T3 (en) 2005-08-19 2024-01-11 Amylin Pharmaceuticals Llc Exendin for use in treating diabetes and reducing body weight
CN104324366B (en) 2005-09-14 2016-10-05 曼金德公司 Method for preparation of drug based on improving the active agent affinity to crystalline microparticle surfaces
KR101368525B1 (en) 2005-09-20 2014-03-06 노파르티스 아게 Use of a dpp-iv inhibitor to reduce hypoglycemic events
US8759290B2 (en) 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
US7687608B2 (en) 2005-10-19 2010-03-30 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007064691A1 (en) 2005-12-02 2007-06-07 Nabil Habib Lab Treatment of cancer and other diseases
RU2008124109A (en) 2005-12-08 2010-01-20 МДРНА, Инк. (US) TRANSMISSION DELIVERY OF STABILIZED EXCENDIN COMPOSITIONS
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
RU2427383C2 (en) 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи High stability pharmaceutical compositions
EP1988922A4 (en) 2006-02-03 2010-06-02 Medimmune Llc Protein formulations
US7704953B2 (en) 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
BRPI0710651A2 (en) 2006-04-13 2011-08-23 Sod Conseils Rech Applic pharmaceutical compositions of hglp-1, expedina-4 and their analogues and their use
RU2409349C2 (en) 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Pharmaceutical compositions, containing glucagon-like peptide (glp-1)
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP2029160A2 (en) 2006-05-12 2009-03-04 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
KR20090031368A (en) 2006-05-26 2009-03-25 아밀린 파마슈티칼스, 인크. Compositions and method for treatment of congestive heart failure
US8114632B2 (en) 2006-06-21 2012-02-14 Biocon Limited Method of producing biologically active polypeptide having insulinotropic activity
EP2051697A2 (en) 2006-07-05 2009-04-29 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
ATE524493T1 (en) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp EXENDIN FUSION PROTEINS
US7928186B2 (en) 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
WO2008016729A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
CN101125207B (en) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 Exendin or its analogs with polyethylene group and its preparation and application
EP2124883A2 (en) 2006-12-12 2009-12-02 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations and methods for making the same
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN101663317A (en) * 2007-01-05 2010-03-03 CovX科技爱尔兰有限公司 glucagon-like protein-1 receptor (glp-1r) agonist compounds
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
ES2628063T3 (en) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Glucagon analogs showing greater solubility in physiological pH buffers
RU2432361C2 (en) 2007-01-05 2011-10-27 КовЭкс Текнолоджиз Айэлэнд Лимитед Glucagon-like protein-1 receptor (glp-1r) agonist compounds
WO2008098212A2 (en) 2007-02-08 2008-08-14 Diobex, Inc. Extended release formulations of glucagon and other peptides and proteins
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
US8420598B2 (en) 2007-04-20 2013-04-16 B & L Delipharm Corp. Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008134425A1 (en) 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US7829664B2 (en) 2007-06-01 2010-11-09 Boehringer Ingelheim International Gmbh Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
CA2689909C (en) 2007-06-08 2016-04-05 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
KR20100020516A (en) 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Glp-1-fc fusion protein formulation
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN101366692A (en) 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 Stable Exenatide formulation
EP2193142B1 (en) 2007-08-30 2015-01-07 CureDM Group Holdings, LLC Compositions and methods of using proislet peptides and analogs thereof
CN101842109B (en) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 Peptides derivatized with A-B-C-D- and their therapeutical use
JP2010538069A (en) 2007-09-07 2010-12-09 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Exendin-4 and analogs of exendin-3
KR20130123470A (en) 2007-10-24 2013-11-12 맨카인드 코포레이션 Delivery of active agents
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
AU2008316634B2 (en) 2007-10-24 2014-02-27 Mannkind Corporation Method of preventing adverse effects by GLP-1
MX2010004297A (en) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Glucagon antagonists.
MX2010004298A (en) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compounds exhibiting glucagon antagonist and glp-1 agonist activity.
CN107412742B (en) 2007-11-16 2022-03-15 诺沃—诺迪斯克有限公司 Pharmaceutical composition comprising a GLP-1 peptide or exendin-4 peptide and a basal insulin peptide
EP2224945B1 (en) 2007-11-23 2012-05-16 Michael Rothkopf Methods of enhancing diabetes resolution
CN101444618B (en) 2007-11-26 2012-06-13 杭州九源基因工程有限公司 Pharmaceutical preparation containing exenatide
US20090186819A1 (en) 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
EP2229407B1 (en) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Novel insulin derivatives having an extremely delayed time-action profile
JP2011511778A (en) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Ester-based peptide prodrugs
RS58948B1 (en) 2008-02-01 2019-08-30 Ascendis Pharma As Prodrug comprising a self-cleavable linker
MY161108A (en) 2008-02-06 2017-04-14 Biocon Ltd Fermentation medias and processes thereof
WO2009114959A1 (en) 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 Injectalble sustained-release pharmaceutical formulation and method for preparing it
US20110034385A1 (en) 2008-04-07 2011-02-10 National Institute Of Immunology Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder
RU2517135C2 (en) 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Peptide compositions and methods for production thereof
ES2552646T3 (en) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
JP2011523052A (en) 2008-05-23 2011-08-04 アミリン・ファーマシューティカルズ，インコーポレイテッド GLP-1 receptor agonist bioassay
DE202009018480U1 (en) 2008-06-13 2012-01-26 Mannkind Corp. Dry powder inhaler and drug delivery system
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
AU2009261441B2 (en) 2008-06-17 2013-01-10 Glytech, Inc. Oligosaccharide chain added glp-1 peptide
TWI474832B (en) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
MX2010013453A (en) 2008-06-17 2011-01-21 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity.
MX2010012695A (en) 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers.
CN102131516B (en) 2008-06-27 2016-03-16 杜克大学 Comprise the therapeutic agent of elastin-like peptides
EP2303247A4 (en) 2008-07-21 2012-08-01 Syneron Medical Ltd Transdermal system for extended delivery of incretins and incretin mimetic peptides
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
CN101670096B (en) 2008-09-11 2013-01-16 杭州九源基因工程有限公司 Medicinal preparation containing exenatide
CR20170369A (en) 2008-10-17 2017-11-01 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST (Divisional 2011-0188)
PT2373681T (en) 2008-12-10 2017-04-11 Glaxosmithkline Llc Pharmaceutical compositions of albiglutide
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
BRPI0823377A2 (en) 2008-12-15 2016-09-27 Zealand Pharma As glucagon analogs
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
CN101538323B (en) 2009-01-13 2012-05-09 深圳翰宇药业股份有限公司 Method for purifying Exenatide
DE102009006602A1 (en) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
KR101733816B1 (en) 2009-03-04 2017-05-08 맨카인드 코포레이션 An improved dry powder drug delivery system
DK2403569T3 (en) 2009-03-05 2014-07-21 Sanofi Aventis Deutschland PHARMACEUTICAL DELIVERY DEVICE
US8642544B2 (en) 2009-04-01 2014-02-04 Amylin Pharmaceuticals, Llc N-terminus conformationally constrained GLP-1 receptor agonist compounds
WO2010118034A2 (en) 2009-04-06 2010-10-14 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
CN102439044B (en) 2009-04-22 2014-08-13 阿特根公司 In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
CN101870728A (en) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 Novel Exendin variant and conjugate thereof
CN101559041B (en) 2009-05-19 2014-01-15 中国科学院过程工程研究所 Polypeptide medicament sustained release microsphere or microcapsule preparation with uniform grain size and preparation method thereof
WO2010133676A1 (en) 2009-05-20 2010-11-25 Sanofi-Aventis Deutschland Gmbh A system comprising a drug delivery device and a cartridge provided with a bung and a method of identifying the cartridge
CN105536110B (en) 2009-05-20 2020-01-17 赛诺菲-安万特德国有限公司 Stopper for medicament containing cartridge in medicament delivery device
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc Glp-1 receptor agonist compounds for sleep enhancement
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
RU2012101274A (en) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon Compounds Active Against the GIP Receptor
IN2012DN00248A (en) 2009-07-02 2015-05-01 Angiochem Inc
EA022816B1 (en) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Acylated glucagon analogues
CN101601646B (en) 2009-07-22 2011-03-23 南京凯瑞尔纳米生物技术有限公司 Nasal cavity drop for treating diabetes and preparation method thereof
WO2011011675A1 (en) 2009-07-23 2011-01-27 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
KR20120089843A (en) 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 Prodrugs comprising an insulin linker conjugate
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
CN101993485B (en) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
SG10201406063XA (en) 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
WO2011049713A2 (en) 2009-10-22 2011-04-28 Biodel Inc. Stabilized glucagon solutions
US20110097386A1 (en) 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
JPWO2011052523A1 (en) 2009-10-30 2013-03-21 株式会社糖鎖工学研究所 Glycoadducts of antigenic GLP-1 analogs
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
EP3345593B1 (en) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
EP3417871B1 (en) 2009-11-13 2020-12-23 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising a glp-1-agonist, an insulin, and methionine
US20130053350A1 (en) 2009-12-15 2013-02-28 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
JP2013514371A (en) 2009-12-15 2013-04-25 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー PPARγ-preserving thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
WO2011084456A1 (en) 2009-12-15 2011-07-14 Metabolic Solutions Development Company Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
RU2564661C2 (en) 2009-12-15 2015-10-10 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Thiazolidinedione salts with reduced affinity to ppar for treatment of metabolic disorders
AU2010338387B2 (en) 2009-12-16 2014-10-23 Novo Nordisk A/S Double-acylated GLP-1 derivatives
CN102933200B (en) 2009-12-18 2015-11-25 莱迪杜德制药公司 Comprise the single-phase gels compositions of phospholipid
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CN101798588B (en) * 2009-12-21 2015-09-09 上海仁会生物制药股份有限公司 GLP-1 receptor stimulant Determination of biological activity method
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Oxyntomodulin peptide analogue ‎
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
CN102892425A (en) 2010-01-20 2013-01-23 西兰制药公司 Treatment of cardiac conditions
EP2528618A4 (en) * 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
CN102740909B (en) 2010-02-01 2016-05-04 赛诺菲-安万特德国有限公司 Cartridge case retainer, doser and for cartridge case being fixed on to the method for cartridge case retainer
WO2011109784A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates
CN102917748B (en) 2010-03-24 2015-04-01 施菲姆德控股有限责任公司 Intravascular tissue disruption
AR080592A1 (en) * 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
CN102918055B (en) 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 New glucagon analogs
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EA201291009A1 (en) 2010-05-20 2013-05-30 Глаксо Груп Лимитед IMPROVED CONNECTING OPTIONS AGAINST SERUM ALBUMIN
US8263554B2 (en) 2010-06-09 2012-09-11 Amylin Pharmaceuticals, Inc. Methods of using GLP-1 receptor agonists to treat pancreatitis
CN101891823B (en) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 Exendin-4 and analog fusion protein thereof
US8636711B2 (en) 2010-06-14 2014-01-28 Legacy Emanuel Hospital & Health Center Stabilized glucagon solutions and uses therefor
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9234023B2 (en) 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
MX2013001131A (en) 2010-07-28 2013-10-17 Amylin Pharmaceuticals Llc Glp-1 receptor agonist compounds having stabilized regions.
CN102397558B (en) 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Positioning pegylation modified compound of Exendin-4 analog and application thereof
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
EA201390450A1 (en) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. POLYPEPTIDES WITH INCREASED DURATION OF ACTION
JP5894174B2 (en) 2010-11-03 2016-03-23 アレコー リミテッド Novel composition comprising glucagon
JP6092113B2 (en) 2010-11-09 2017-03-08 マンカインド コーポレイション Composition for the treatment of migraine comprising serotonin receptor agonist and diketopiperazine
EP2460552A1 (en) 2010-12-06 2012-06-06 Sanofi-Aventis Deutschland GmbH Drug delivery device with locking arrangement for dose button
CN102552883B (en) 2010-12-09 2014-02-19 天津药物研究院 Polypeptide compound, pharmaceutical composition, its preparation method and application thereof
CN105963685B (en) 2010-12-16 2021-01-15 诺和诺德股份有限公司 Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid
US9161953B2 (en) 2010-12-22 2015-10-20 Amylin Pharmaceuticals, Llc GLP-1 receptor agonists for islet cell transplantation
CN103458920B (en) 2010-12-22 2016-07-06 印第安那大学科技研究公司 Show the glucagon analogs of GIP receptor active
CN102532301B (en) 2010-12-31 2014-09-03 上海医药工业研究院 Novel Exendin-4 analogues and preparation method thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102100906A (en) 2011-02-18 2011-06-22 深圳翰宇药业股份有限公司 Medicinal preparation of exenatide and preparation method thereof
WO2012122535A2 (en) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
CN102718858B (en) 2011-03-29 2014-07-02 天津药物研究院 Glucagon-like peptide-1 (GLP-1) analogue monomer and dimer, preparation method therefor and application thereof
CN106928341B (en) 2011-03-30 2021-06-01 上海仁会生物制药股份有限公司 Fixed-point mono-substituted pegylated Exendin analogue and preparation method thereof
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN102766204B (en) 2011-05-05 2014-10-15 天津药物研究院 Glucagon-like peptide-1 mutant polypeptide, its preparation method and application thereof
KR20230023059A (en) 2011-05-18 2023-02-16 메더리스 다이어비티즈, 엘엘씨 Improved peptide pharmaceuticals for insulin resistance
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc Long duration dual hormone conjugates
UA113626C2 (en) 2011-06-02 2017-02-27 A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE
EP3878859B1 (en) 2011-06-10 2023-11-01 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
KR102002783B1 (en) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
JP2014518216A (en) 2011-06-17 2014-07-28 ハロザイム インコーポレイテッド Stable formulation of hyaluronan degrading enzyme
BR112013032375B1 (en) 2011-06-17 2022-09-20 Hanmi Science Co., Ltd CONJUGATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
BR112013032717A2 (en) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp glucagon / glp-1 receptor coagonists
LT2723367T (en) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2014520159A (en) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Method for treating diabetes with sustained-release preparation of GLP-1 receptor agonist
KR101357117B1 (en) 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 PEGylated Exendin-4 analogues or its derivatives, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
CN104271588B (en) 2011-07-08 2017-10-10 安米林药品有限责任公司 The engineered polypeptide of immunogenicity with enhanced acting duration and reduction
JP5950477B2 (en) 2011-08-10 2016-07-13 アドシア Injection solution of at least one basal insulin
WO2013028989A1 (en) 2011-08-24 2013-02-28 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
WO2013029279A1 (en) 2011-09-03 2013-03-07 深圳市健元医药科技有限公司 Novel glp-i analogue, preparation method and use thereof
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
MX359329B (en) 2011-10-28 2018-09-25 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2.
CN102363633B (en) 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 Glucagon like peptide-1 mutant polypeptide and preparation method, medicinal composition and use thereof
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN107261152B (en) 2011-11-29 2022-03-04 优奥斯私人有限公司 Method for preserving injectable pharmaceutical compositions comprising cyclodextrins and hydrophobic drugs
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
AU2012356219B2 (en) 2011-12-22 2016-03-31 Covx Technologies Ireland Limited Anti-diabetic compounds
PE20142113A1 (en) 2011-12-23 2014-12-03 Zealand Pharma As GLUCAGON ANALOGS
WO2013101749A1 (en) 2011-12-29 2013-07-04 Latitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsions
CN107583039A (en) 2012-01-09 2018-01-16 阿道恰公司 PH is 7 and the Injectable solution at least containing the PI basal insulins for being 5.8 to 8.5 and substitution copolymerization (amino acid)
WO2013148966A1 (en) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
WO2013148871A1 (en) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Engineered polypeptides
JP2015513914A (en) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of secreted proteins
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
CN102649947A (en) 2012-04-20 2012-08-29 无锡和邦生物科技有限公司 Cell strain for measuring bioactivity of GLP-1 and functional analogue thereof and application of cell strain
EP2841090A1 (en) 2012-04-24 2015-03-04 Amylin Pharmaceuticals, LLC Site-specific enzymatic modification of exendins and analogs thereof
US20130289241A1 (en) 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
US8901484B2 (en) 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
EP2844670B1 (en) 2012-05-03 2017-12-06 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP2844669B1 (en) * 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP2664374A1 (en) 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
CN103421094A (en) 2012-05-24 2013-12-04 上海医药工业研究院 Polypeptide compound with EPO-like activity
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
CN104583234A (en) 2012-06-14 2015-04-29 赛诺菲 Exendin-4 peptide analogues
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
DK2864350T3 (en) 2012-06-21 2018-05-28 Univ Indiana Res & Tech Corp ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY
KR102264177B1 (en) 2012-07-12 2021-06-11 맨카인드 코포레이션 Dry powder drug delivery systems and methods
EP2875043B1 (en) 2012-07-23 2016-12-21 Zealand Pharma A/S Glucagon analogues
AR094821A1 (en) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
AR092862A1 (en) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
EP2934562A1 (en) 2012-08-14 2015-10-28 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
WO2014027254A1 (en) 2012-08-14 2014-02-20 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
CN102816244A (en) 2012-08-23 2012-12-12 无锡和邦生物科技有限公司 Fusion protein of exendin-4 peptide and human serum albumin (HSA) and preparation method thereof
CN102827270A (en) 2012-09-13 2012-12-19 无锡和邦生物科技有限公司 Pegylated exenatide ramification and use thereof
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
MY168536A (en) 2012-11-06 2018-11-12 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
EP3434696A1 (en) 2012-11-20 2019-01-30 Mederis Diabetes, LLC Improved peptide pharmaceuticals for insulin resistance
TWI617574B (en) 2012-12-11 2018-03-11 梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
WO2014096149A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 Derivatives
CN103908657A (en) 2012-12-31 2014-07-09 复旦大学附属华山医院 Use of glucagons-like peptide-1 analogue in preparation of ophthalmic disease drug
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
AU2014230472A1 (en) 2013-03-14 2015-10-01 Medimmune Limited Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
WO2014152460A2 (en) 2013-03-15 2014-09-25 Indiana University Research And Technology Corporation Prodrugs with prolonged action
KR20160021758A (en) 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2014227368A (en) 2013-05-21 2014-12-08 国立大学法人帯広畜産大学 Glucagon analog for treating diabetes mellitus and hyperglycemia condition
CN103304660B (en) 2013-07-12 2016-08-10 上海昂博生物技术有限公司 A kind of synthetic method of Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37]
CN103405753B (en) 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 Stable insulin secretion accelerating peptide liquid drugs injection pharmaceutical composition
CN105745222A (en) 2013-10-17 2016-07-06 西兰制药公司 Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080151A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
TW201609800A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
CN103665148B (en) 2013-12-17 2016-05-11 中国药科大学 A kind of Polypeptide-k of Orally-administrable and method for making thereof and purposes
CN103980358B (en) 2014-01-03 2016-08-31 杭州阿诺生物医药科技股份有限公司 A kind of method preparing Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37]
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6641280B2 (en) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ Stabilized pharmaceutical formulations of insulin analogues and / or insulin derivatives
GB201404002D0 (en) 2014-03-06 2014-04-23 Imp Innovations Ltd Novel compounds
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (en) 2014-09-23 2016-11-09 蒋先兴 Oxyntomodulin analogs
WO2016055610A1 (en) 2014-10-10 2016-04-14 Novo Nordisk A/S Stable glp-1 based glp-1/glucagon receptor co-agonists
MA55068A (en) 2014-10-24 2022-01-05 Merck Sharp & Dohme GLUCAGON AND GLP-1 RECEPTOR CO-AGONISTS
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198604A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Also Published As

Publication number Publication date
IL238650A0 (en) 2015-06-30
US9670261B2 (en) 2017-06-06
AU2013366691A1 (en) 2015-07-09
WO2014096150A1 (en) 2014-06-26
LT2934567T (en) 2018-09-10
CA2895156A1 (en) 2014-06-26
DOP2015000156A (en) 2015-08-31
US9745360B2 (en) 2017-08-29
AU2013366690B2 (en) 2018-02-08
UA116553C2 (en) 2018-04-10
SI2934567T1 (en) 2018-10-30
LT2934568T (en) 2018-02-12
ECSP15031141A (en) 2015-11-30
AR105816A2 (en) 2017-11-15
AR094178A1 (en) 2015-07-15
US20140206609A1 (en) 2014-07-24
CR20150358A (en) 2015-09-16
SI2934568T1 (en) 2018-03-30
US20140221281A1 (en) 2014-08-07
HK1211232A1 (en) 2016-05-20
HUE038748T2 (en) 2018-11-28
KR20150099548A (en) 2015-08-31
BR112015013809A2 (en) 2017-11-14
RS57531B1 (en) 2018-10-31
HK1213483A1 (en) 2016-07-08
MX2015008099A (en) 2016-04-25
EA201591174A1 (en) 2016-03-31
CY1120030T1 (en) 2018-12-12
EP3400957A1 (en) 2018-11-14
RU2652783C2 (en) 2018-05-03
PL2934567T3 (en) 2018-10-31
EP2934567B9 (en) 2018-08-22
US20170216406A1 (en) 2017-08-03
AR094181A1 (en) 2015-07-15
KR20150096398A (en) 2015-08-24
WO2014096145A1 (en) 2014-06-26
RU2015129788A (en) 2017-01-30
JP2016503770A (en) 2016-02-08
IL238692A0 (en) 2015-06-30
EP2934566B1 (en) 2017-06-21
HUE035803T2 (en) 2018-05-28
AR094180A1 (en) 2015-07-15
AU2013360721A1 (en) 2015-07-09
CN104870009B (en) 2021-05-18
TW201443080A (en) 2014-11-16
UY35231A (en) 2014-07-31
HK1211231A1 (en) 2016-05-20
KR20150096684A (en) 2015-08-25
AU2013366692B2 (en) 2017-11-23
CL2015001751A1 (en) 2015-09-21
ZA201503914B (en) 2016-12-21
AU2013366690A1 (en) 2015-07-09
SG11201504215PA (en) 2015-06-29
PE20151239A1 (en) 2015-09-08
DK2934568T3 (en) 2018-01-22
CA2895755A1 (en) 2014-06-26
CA2895875A1 (en) 2014-06-26
AU2013366692A1 (en) 2015-07-09
TW201429985A (en) 2014-08-01
SG10201705097PA (en) 2017-07-28
BR112015014800A2 (en) 2017-10-10
RU2015129815A (en) 2017-01-27
AR099912A1 (en) 2016-08-31
HRP20180092T1 (en) 2018-02-23
MX2015008077A (en) 2015-10-30
CN104902919B (en) 2018-11-20
EP2934567B1 (en) 2018-05-09
CN104902918A (en) 2015-09-09
IL239101A0 (en) 2015-07-30
PH12015501291B1 (en) 2015-08-24
PL2934568T3 (en) 2018-03-30
US20140213513A1 (en) 2014-07-31
UY35232A (en) 2014-07-31
TW201441251A (en) 2014-11-01
MA38276A1 (en) 2017-06-30
US10253079B2 (en) 2019-04-09
WO2014096149A1 (en) 2014-06-26
JP2016506401A (en) 2016-03-03
TN2015000283A1 (en) 2016-10-03
PT2934568T (en) 2018-01-04
RU2015129696A (en) 2017-01-27
DK2934567T3 (en) 2018-08-13
CL2016002182A1 (en) 2018-01-12
MX2015008079A (en) 2015-10-30
CN104902920A (en) 2015-09-09
JP6391589B2 (en) 2018-09-19
BR112015014510A2 (en) 2017-11-21
IL238623A0 (en) 2015-06-30
US20140206608A1 (en) 2014-07-24
UY35234A (en) 2014-07-31
MA38276B1 (en) 2018-03-30
EP2934569A1 (en) 2015-10-28
MX362190B (en) 2019-01-08
ES2688367T3 (en) 2018-11-02
CN104870009A (en) 2015-08-26
HK1211233A1 (en) 2016-05-20
EP2934567A1 (en) 2015-10-28
CN104902919A (en) 2015-09-09
WO2014096148A1 (en) 2014-06-26
TWI600663B (en) 2017-10-01
EA031428B1 (en) 2018-12-28
KR20150096433A (en) 2015-08-24
PH12015501291A1 (en) 2015-08-24
CA2894765A1 (en) 2014-06-26
JP2016503772A (en) 2016-02-08
CY1121153T1 (en) 2020-05-29
EP2934566A1 (en) 2015-10-28
PT2934567T (en) 2018-10-01
UY35233A (en) 2014-07-31
JP6408998B2 (en) 2018-10-17
MX360317B (en) 2018-10-29
TWI602828B (en) 2017-10-21
TW201441252A (en) 2014-11-01
HRP20181300T1 (en) 2018-10-05
EP2934568A1 (en) 2015-10-28
EP2934568B1 (en) 2017-10-18
SG11201503576XA (en) 2015-06-29
SG11201503524PA (en) 2015-06-29
JP2016503771A (en) 2016-02-08
MX2015008114A (en) 2015-11-06
ES2653765T3 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
HK1213483A1 (en) Dual glp1/gip or trigonal glp1/gip/glucagon agonists glp1/gip glp1/gip/
ZA201501694B (en) Exendin-4 derivatives as dual glp1/glucagon agonists
HK1213292A1 (en) Constitutive promoter
EP2981522A4 (en) Ppar agonists
GB201318793D0 (en) Vascular Biomarkers
EP2997482A4 (en) Multi-mode agent
GB201311067D0 (en) Dual curable composition
SG11201510197RA (en) Connecting Mechanism
HK1188905A2 (en) Double-sided watch
IL243730A0 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists
GB201308400D0 (en) Anti-ligature mechanism
AU349690S (en) Dinner fork
GB201318422D0 (en) Organiser mechanism
EP3031535A4 (en) Melter
GB201320894D0 (en) CSF-1 Therapeutics
GB201322793D0 (en) Traverse mechanism
GB201311570D0 (en) Dual Purpose Dartboard
GB201302535D0 (en) Dual Orientation Fixed ID Holder
HU4273U (en) Ware container-case
AU2013235V (en) AF001 Acacia fimbriata
GB201304115D0 (en) Fusion ploypeptide